Compass Financial Management LLC acquired a new stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,260 shares of the exchange traded fund’s stock, valued at approximately $733,000.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Axiom Investment Management LLC purchased a new stake in SPDR S&P Biotech ETF during the 1st quarter valued at $26,000. Financial Life Planners purchased a new position in shares of SPDR S&P Biotech ETF in the 1st quarter worth $27,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of SPDR S&P Biotech ETF in the 4th quarter worth $27,000. Intesa Sanpaolo Wealth Management purchased a new position in shares of SPDR S&P Biotech ETF in the 4th quarter worth $30,000. Finally, SHP Wealth Management bought a new stake in shares of SPDR S&P Biotech ETF in the fourth quarter worth $31,000.
SPDR S&P Biotech ETF Stock Performance
SPDR S&P Biotech ETF stock opened at $165.73 on Monday. The stock has a market cap of $10.82 billion, a PE ratio of 11.47 and a beta of 0.83. SPDR S&P Biotech ETF has a one year low of $88.60 and a one year high of $169.68. The stock has a fifty day moving average of $153.99 and a 200 day moving average of $137.76.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Recommended Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
